Michael B. Kastan

Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured in the media, trades, journals, at Duke and the DCI blog.

The Duke BioRepository & Precision Pathology Center, a Duke School of Medicine Service Center and DCI Shared Resource turns 10.

Learn how the Precision Cancer Medicine Initiative is advancing research, extending lives, and breaking down barriers to access.

The 2022 Shingleton Society dinner honored four awardees for their service in advancing the fight against cancer and paid video tribute to Cancer Center founder William Shingleton, MD.

Trudy G. Oliver, PhD, has joined DCI from the Huntsman Cancer Institute as a Duke Science and Technology Scholar. Her research focuses on subtypes of lung cancer.

Clinical providers, researchers, staff & health leaders came together to celebrate the 50th anniversary of the Duke Comprehensive Cancer Center (now DCI).

DCI member Joseph Heitman, MD, PhD, chair of the Department of Molecular Genetics and Microbiology, elected to National Academy of Sciences.

Research led by Duke Cancer Institute’s Jen-Tsan Ashley Chi, MD, PhD, could have implications for the successful treatment of ovarian, breast and kidney cancer.

DCI director Michael B. Kastan, MD, PhD, announced a planned reconfiguration of DCI’s NCI-Designated Research Programs and welcomed new research leaders.

One top trainee from each of the eight DCI Research Programs presented their pioneering cancer research projects. Benjamin Mayro received the Bell Award.

Join Dr. Kastan and Team DCI for a virtual training Victory Ride, May 16. Choose a V-Ride route or your own path on a cycle or stationary bike.

April is Volunteer Appreciation Month. Take a moment to thank a volunteer.

Exec. director of DCI, Michael Kastan, MD, PhD, was one of 97 to sign an AACI letter imploring the president to use the DFA in the COVID-19 emergency.

Suzanne L. Topalian, MD, Sidney Kimmel Comprehensive Cancer Center, delivers the Thomas J. Matthews Endowed Lecture, March 11 via livestream.

After many months of preparation and an extensive review process, DCI was renewed as an NCI-designated Comprehensive Cancer Center for another five-year period.

As we pursue multiple avenues in our mission to reduce the burden of cancer, we don’t limit ourselves to the bedside or the research lab. We count on our partners to help.

Inspired by the bravery of our cancer patients, we don’t shrink from even the most daunting challenges; from reducing risk to solving intractable problems.

Ten years, twelve years, even more than two decades. That is how long some of DCI’s patients with prostate and other urologic cancers are liv­ing past their diagnoses.